mRNA Cancer Vaccines

About RNAimmune

RNAimmune is an emerging biotech player in the mRNA space, spun out from Sirnaomics in 2020. The company is advancing a pipeline of mRNA-based prophylactic vaccines and cancer immunotherapies, with its lead RSV vaccine candidate having entered Phase 1 clinical trials in the US. Backed by a $27 million Series A round, RNAimmune is building on a foundation of over 20 years of mRNA expertise and has established key partnerships and licensing deals, particularly in China, to advance its programs.

Therapeutic Areas